Alexander P Boardman

Oct 13, 2024 | nature.com | Jennifer K Lue |Alexander P Boardman |Steven Horwitz |Andrew M. Intlekofer |Anita Kumar |Ariela Noy | +4 more

Dear Editor,High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH) is a group of aggressive lymphomas that are associated with poor outcomes when treated with R-CHOP [1, 2]. Conflicting data exists regarding the outcomes of HGBCL with MYC and BCL2 rearrangements (DH-BCL2) as compared to HGBCL with MYC and BCL6 translocations (DH-BCL6) [3,4,5,6].

Jun 9, 2023 | onlinelibrary.wiley.com | Alexander P Boardman |Gilles Salles

1 CAR T-CELL THERAPY IN THIRD AND SUBSEQUENT LINES FOR LBCL Second generation CD19-CAR T-cells bearing a crucial costimulatory molecule first demonstrated pre-clinical efficacy in hematologic malignancies in 2003.1 Since then, several of these products have led to impressive response rates and durable remissions in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), including large B cell lymphoma (LBCL).2-18 Axicabtagene ciloleucel (axi-cel; KTE-C19) is an...